EU Acceptance Of Foreign Comparators For Biosimilar Applications Will Boost Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Union has announced that it will accept a reference product for a biosimilar application from countries with robust regulatory systems and similar guidelines, a move that should significantly boost the domestic biosimilars industry.
You may also be interested in...
Europe’s Revised Biosimilars Guideline Allows Non-EU Data In Applications
Some data from a non-European version of a reference product can be used in biosimilar marketing applications, a revised overarching biosimilars guideline from European regulators says. It also notes interchangeability is a matter for individual European countries to decide.
Biosimilars’ Next Hurdle In EU Is Physician Opposition To Extrapolation
As Europe gears up to approve and publish a global development plan for biosimilars, doctors’ reluctance to support extrapolation of indications for these drugs could be costly stumbling block for industry.
Biosimilars Development In EU Could Get Easier; EC Mulls Accepting Outside Data
Industry applauds a suggestion by a senior healthcare representative that the European Commission could re-examine the overarching guideline on biosimilars to promote global development, but growth ultimately will be determined by greater worldwide harmonization.